First Trust Cloud Comput... Aktie - SKYE

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

40,20

Gebot

39,77

Fragen

40,635

Volumen

545

40,18 Tagesbereich 41,68

0,00 52-Wochen-Bereich 0,00

Handelsende

41,105

Handelsbeginn

41,68

Letzte Trade

40.244999

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

FORT LAUDERDALE, Fla., May 21 /PRNewswire/ -- Newbridge Securities Corporation today announced the quarterly rebalancing and reconstitution of...

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

LONDON, Oct. 4 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) today announces positive results of a Phase III clinical...

SkyePharma to Reorganise Certain Management Functions

LONDON, Sept. 22 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP) ( NASDAQ: SKYE) announces today that as part of the Company's ongoing...

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

Euro 15 million upfront and Euro 70 million in milestones Double Digit Royalties LONDON, Sept. 6 /PRNewswire-FirstCall/ -- SkyePharma PLC...

SkyePharma to Announce 2006 Interim Results on 28 September

LONDON, Sept. 5 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKPLSE:Nasdaq:LSE:SKYE) announces today that the Company will issue its interim...

SkyePharma PLC - Annual General Meeting Statement

LONDON, June 28 /PRNewswire-FirstCall/ -- The Annual General Meeting of SkyePharma plc (LSE:SKPLSE:Nasdaq:LSE:SKYE) was held in London today...

SkyePharma's Chief Operating Officer Appointed to Board

LONDON, May 17 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces the appointment of Dr Ken Cunningham, Chief Operating...

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) and Kos Pharmaceuticals, Inc. (Nasdaq: KOSP, "Kos") will host a...

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

LONDON, May 8 /PRNewswire-FirstCall/ -- SkyePharma PLC (LSE:SKP)(NASDAQ: SKYE) announces today that it has entered into an agreement with Kos...

SkyePharma Announces First European Approval of DepoDur(TM)

Innovative Single Epidural Injection 48 Hours of Post-Surgical Pain Relief LONDON, April 28 /PRNewswire-FirstCall/ -- SkyePharma PLC...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
E3O1Nexoptic Technology Corp	0,013 € (52,94%)	7,63k
VOPInvestigator Resources Ltd	0,0175 € (40,00%)	4,89k
IAHInternational Lithium Corp	0,0145 € (38,10%)	20,1k
K6SMira Pharmaceuticals Inc	1,20 € (37,93%)	3,67k
B5S0NU E Power Corp	0,283 € (36,06%)	76,19k
9COCorus Entertainment	0,0335 € (-43,70%)	460
C0MCCS Abwicklungs AG	0,08 € (-42,45%)	196,61k
47GAGo Metals Corp	0,0142 € (-36,61%)	4,13k
M0YNMynaric AG	0,866 € (-35,85%)	429,67k
WIG1Wige Media AG	0,017 € (-35,85%)	1,44M
D7GNel ASA	0,28 € (-11,81%)	36,74M
RQ0DWave Quantum Inc	6,384 € (19,95%)	3,19M
DRHDroneShield Limited	0,575 € (7,68%)	2,21M
DMLSayona Mining Limited	0,0115 € (-4,96%)	1,88M
WIG1Wige Media AG	0,017 € (-35,85%)	1,44M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

First Trust Cloud Computing Ucits Etf (SKYE)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

SKYE Neueste Nachrichten

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

SkyePharma to Reorganise Certain Management Functions

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

SkyePharma to Announce 2006 Interim Results on 28 September

SkyePharma PLC - Annual General Meeting Statement

SkyePharma's Chief Operating Officer Appointed to Board

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

SkyePharma Announces First European Approval of DepoDur(TM)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

First Trust Cloud Computing Ucits Etf (SKYE) Börsenkurse

First Trust Cloud Computing Ucits Etf (SKYE)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

SKYE Neueste Nachrichten

Newbridge Announces Nanotechnology Index (NYSEArca: NNIX) Quarterly Rebalance and Inside Nanotechnology 2Q07 Research Report Rel

SkyePharma Reports Positive Phase III and EU Filing for Lodotra(TM)

SkyePharma to Reorganise Certain Management Functions

SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe

SkyePharma to Announce 2006 Interim Results on 28 September

SkyePharma PLC - Annual General Meeting Statement

SkyePharma's Chief Operating Officer Appointed to Board

SkyePharma and Kos to Host Teleconference Today on US Marketing and Distribution Agreement for Flutiform(TM)

SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States

SkyePharma Announces First European Approval of DepoDur(TM)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	SP
4	0	0	0	0	0	0	0	SP
12	0	0	0	0	0	0	0	SP
26	0	0	0	0	0	0	0	SP
52	0	0	0	0	0	0	0	SP
156	0	0	0	0	0	0	0	SP
260	0	0	0	0	0	0	0	SP